Aveanna Healthcare (AVAH) reported $589.55 million in revenue for the quarter ended June 2025, representing a year-over-year increase of 16.8%. EPS of $0.18 for the same period compares to $0.01 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $536.3 million, representing a surprise of +9.93%. The company delivered an EPS surprise of +350%, with the consensus EPS estimate being $0.04.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Aveanna performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Hours - PDS: 11,053.00 hrs versus the two-analyst average estimate of 10,736.40 hrs.
- Revenue rate - MS: $477.24 versus $467.53 estimated by two analysts on average.
- Unique patients served (UPS) - MS: 91 versus 89 estimated by two analysts on average.
- Revenue rate - PDS: $43.97 compared to the $40.19 average estimate based on two analysts.
- Revenue- PDS: $486.01 million versus the three-analyst average estimate of $437.86 million. The reported number represents a year-over-year change of +19.2%.
- Revenue- MS: $43.43 million versus the three-analyst average estimate of $41.98 million. The reported number represents a year-over-year change of +2.2%.
- Revenue- HHH: $60.11 million versus the three-analyst average estimate of $55.81 million. The reported number represents a year-over-year change of +10%.
View all Key Company Metrics for Aveanna here>>>
Shares of Aveanna have returned -8.9% over the past month versus the Zacks S&P 500 composite's +1.2% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Aveanna Healthcare Holdings Inc. (AVAH): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
